Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Nov '18 Dec '17 Nov '17
Piotroski F-Score
3 1 3 3 5 — — — — —
P/E ratio
0.00 0.00 0.00 0.00 2.00 5.01 0.00 0.00 0.00 0.00
P/S ratio
7.69 26.93 1.37 1.97 12.54 19.01 3.05 5.60 6.31 5.40
Altman Z-Score
(352.42) (29.89) (0.96) (0.64) (2.73) (1.11) (0.74) (0.31) 11.85 (1.50)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.18 20.69
Altman Z″-Score (non-manufacturers)
(868.26) (70.52) (2.41) (4.63) (6.92) (2.13) (2.85) (2.22) (7.90) (6.51)
Beneish M-Score
— — (1.20) — — — — (0.54) — (4.52)
P/Operating CF
(3.79) (28.43) (4.57) (28.37) (2.12) (27.40) (14.60) (15.49) (32.61) (27.90)
P/B ratio
0.00 0.00 1.69 1.81 1.82 12.20 2.34 3.01 3.83 3.28
Price to Tangible BV
0.00 0.00 4.40 3.80 3.10 0.00 0.00 0.00 0.00 0.00
EV/Sales
23.15 66.20 1.69 2.10 8.07 22.19 2.54 4.81 6.81 5.90
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(1.40) (2.36) (2.44) (2.78) (0.79) (6.54) (3.11) (5.25) 18.98 16.44
EV/FCF
(1.38) (2.07) (1.64) (2.15) (0.78) (3.42) (2.28) (3.96) 26.10 22.60
Quick Ratio
0.03 0.12 2.67 1.39 3.00 0.06 1.47 1.61 0.34 0.34
Current Ratio
0.03 0.25 2.91 1.68 3.08 1.85 1.64 1.77 0.43 0.43
Net Debt/EBITDA
(0.42) (0.40) (1.42) (0.32) 0.36 (0.68) 0.75 1.06 (0.56) (0.50)
Debt/Assets
1,235.53% 153.18% 19.73% 18.01% 14.65% 14.00% 6.13% 4.94% 19.29% 19.58%
Debt/Equity
(0.44) (1.06) 0.62 0.28 0.22 2.13 0.17 0.13 0.54 0.55
Asset Turnover
0.13 0.01 0.48 0.52 0.09 0.05 0.27 0.32 0.25 0.28
Operating CF/Net income
0.35 0.27 1.67 1.49 (70.31) 0.55 0.76 0.86 0.31 0.31
Capex/Depreciation
(0.13) (1.34) (6.15) (4.22) (1.06) (3.17) (2.11) (2.12) 0.00 (0.38)
Interest Coverage
(8.82) (21.46) (5.13) (13.00) (90.27) (26.07) (5.37) (4.70) — (4.59)
ROE
164.62% (1,368.97%) (43.98%) (39.52%) 3.78% (146.95%) (79.78%) (85.53%) (87.57%) (92.92%)
ROA
(605.73%) (104.97%) (19.75%) (26.25%) 1.30% (29.00%) (29.60%) (31.72%) (31.02%) (33.72%)
ROIC
0.00% 0.00% (15.55%) (24.17%) (322.83%) (74.42%) (64.80%) (57.52%) 0.00% (38.12%)
Return on Tangible Assets
188.28% 509.96% (27.96%) (87.36%) 3.01% (63.11%) (94.62%) (73.01%) 273.91% 273.91%
Average Days of Receivables
14.11 376.02 366.60 158.47 155.22 190.50 182.74 218.98 79.95 79.95
Research and Development Expense of Revenue
929.66% 2,004.34% 60.88% 100.75% 1,089.69% 346.06% 38.50% 34.65% 23.47% 24.56%
Selling, General and Administrative Expense of Revenue
1,432.08% 6,629.06% 43.27% 41.43% 247.95% 293.69% 89.17% 87.39% 91.08% 91.08%
Intangible Assets out of Total Assets
0.00 0.59 0.20 0.34 0.28 0.09 0.43 0.42 0.65 0.65
Share Based Compensation of Revenue
308.60% 87.36% 2.73% 4.92% 260.00% 146.14% 24.86% 23.39% 0.00% 33.34%
Graham Net Nets
(4.79) (2.20) (0.32) 0.07 0.26 (0.11) (0.30) (0.19) (0.34) (0.40)
Graham Number
48.05 45.95 0.00 0.00 111.89 28.28 0.00 0.00 0.00 0.00
Earnings Yield
(608.99%) (263.70%) (24.74%) (25.69%) 49.99% 19.96% (35.17%) (22.92%) (30.21%) (35.31%)
Free Cash Flow Yield
(217.87%) (118.65%) (75.41%) (49.68%) (82.93%) (34.09%) (36.51%) (21.71%) 4.14% 4.83%
Revenue per Share
0.25 0.18 14.35 14.63 3.59 2.45 15.33 13.95 1.04 10.42
Operating CF per Share
(4.06) (5.11) (9.93) (11.07) (36.61) (8.31) (12.53) (11.73) (0.40) (3.96)
Capex per Share
(0.06) (0.72) (4.85) (3.24) (0.71) (7.57) (4.55) (4.15) 0.00 (1.01)
Free Cash Flow per Share
(4.12) (5.84) (14.78) (14.31) (37.32) (15.89) (17.09) (15.88) (0.40) (4.97)
Cash per Share
0.16 0.51 2.54 2.46 21.37 0.36 11.22 12.30 0.36 3.64
Shareholders Equity per Share
(8.91) (7.23) 11.58 15.91 24.73 3.82 20.00 21.42 1.46 14.59
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(8.91) (7.23) 11.58 15.91 24.73 3.82 20.00 21.42 1.46 14.59
Free Cash Flow
(17.34) (16.93) (37.09) (34.73) (79.56) (25.27) (22.85) (21.24) (3.83) (4.81)
Working Capital
(26.16) (12.33) 30.41 10.39 33.79 35.91 10.90 13.15 (9.62) (9.62)
Capital Expenditures
(0.26) (2.10) (12.17) (7.87) (1.52) (12.05) (6.09) (5.56) (0.97) (0.97)
Net Current Asset Value
(38.12) (31.46) (15.54) 4.55 25.12 (8.07) (19.07) (16.50) (14.85) (18.45)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.25 3.95 0.34 0.22 0.20 3.09 0.30 0.30 0.00 0.10
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
3.61 1.06 0.09 0.18 0.47 1.65 0.23 0.22 0.51 0.51
Cash ROIC
86.03% (607.57%) (69.49%) (62.71%) (72.54%) (128.92%) (49.37%) (43.49%) (15.13%) (18.89%)
Accounts Receivable Turnover
3.53 0.03 1.40 3.80 2.89 0.63 1.91 2.78 4.57 4.64
Accounts Payable Turnover
0.20 1.14 1.06 5.28 11.83 2.77 2.87 2.80 2.18 1.61
Inventory Turnover
0.00 81.23 43.13 241.87 523.28 15.61 7.09 8.80 11.79 12.10
Average Days of Payables
2,484.39 384.20 314.94 52.17 37.59 144.53 138.88 128.28 167.13 209.87
Days of Inventory on Hand
0.00 1.98 8.53 1.18 0.80 3.54 50.30 58.54 30.96 38.88
Average Receivables
0.29 18.36 25.80 9.33 2.64 6.15 10.73 6.70 2.21 2.17
Average Payables
9.85 5.51 4.83 6.94 7.10 5.07 4.19 3.86 3.91 4.23
Average Inventory
— 0.08 0.12 0.15 0.16 0.90 1.70 1.23 0.73 0.56
Average Assets
7.95 52.74 75.38 68.76 85.09 83.19 74.66 57.66 39.87 36.68
Average Common Equity
(29.26) 4.04 33.85 45.68 29.40 16.41 27.70 21.39 14.12 13.31

Fold the line items

Columns are period end dates